Poongjeon Pharmacy

At a glance

Poongjeon Pharmacy filed 68 disclosures in the last 12 months, including 6 insider, 5 5% holder, 3 issuance and 1 m&a. The most recent key filing was on Oct 26: Issuing 1,200,000 sh of new shares, equal to 12.5% of existing shares.

Revenue for 2025 was ₩23.8B, up 2790.3% on 2024. It made an operating loss of ₩4.5B. Debt was 44% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩27.2B and operating loss of ₩2.5B.

The 2025 annual report lists 25 employees with an average tenure of 2.7 years and average pay of ₩37.2M. Its 6 directors and auditors were paid ₩57.8M each on average. It paid no cash dividend for 2025. 마르시아 신기술조합 제77호 and related parties held 40.74% at year end.

From the 2025 annual report

Staff: 25 (15 men, 10 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩1.5B. Directors and auditors: 6, paid ₩346.8M in total.

No cash dividend was paid for 2025.

Largest shareholder

마르시아 신기술조합 제77호 holds 25.56%; with 2 related parties the group holds 40.74% of common shares at year end (from 26.22% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary